Loading…
Loading…
See exactly how IBD's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for IBD and 80,000+ other tickers.
The Inspire Corporate Bond ETF primarily invests in high-quality debt securities issued by large American corporations that are selected for their inspiring and biblically aligned principles. This fund aims to mirror the performance outcomes of the Inspire Corporate Bond Index.
Oppenheimer on Thursday initiated coverage of Palisade Bio Inc. (NASDAQ:PALI) , saying the stock offers investors an attractive way to gain exposure to the fast-growing inflammatory bowel disease market.
Is the federal government's clash with Anthropic a warning sign for the entire artificial intelligence ecosystem? Tech strategist and Georgetown adjunct law professor Emily Benson breaks down the regulatory fallout for AI developers and investors.
The AI buildout's real bottleneck is the steel, copper, and chilled water surrounding the GPUs.
A smart beta exchange traded fund, the Inspire Corporate Bond ETF (IBD) debuted on 07/10/2017, and offers broad exposure to the Investment Grade Corporate Bond ETFs category of the market.
AbbVie presents 18 abstracts in Crohn's disease and ulcerative colitis Breadth of data from real-world evidence and clinical trials reinforce risankizumab and upadacitinib efficacy, safety profile, and durability NORTH CHICAGO, Ill., May 5, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the presentation of new data across its gastroenterology portfolio at the 2026 Digestive Disease Week (DDW) Annual Meeting, May 2-5 in Chicago.